Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatmentin vivo

Development of recurrent platinum resistant disease following chemotherapy presents a challenge in managing ovarian cancer. Using tumors derived from genetically defined mouse ovarian cancer cells, we investigated the stem cell properties of residual cells post-chemotherapy. Utilizing CD133 and Sca-...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2013-10, Vol.339 (2), p.237
Main Authors: Kulkarni-Datar, Kashmira, Orsulic, Sandra, Foster, Rosemary, Rueda, Bo R
Format: Article
Language:English
Subjects:
Cancer therapies
Cell cycle
Chemotherapy
Flow cytometry
Laboratory animals
Ovarian cancer
Population
Stem cells
Tumors
Womens health
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Development of recurrent platinum resistant disease following chemotherapy presents a challenge in managing ovarian cancer. Using tumors derived from genetically defined mouse ovarian cancer cells, we investigated the stem cell properties of residual cells post-chemotherapy. Utilizing CD133 and Sca-1 as markers of candidate tumor initiating cells (TIC), we determined that the relative levels of CD133+and Sca-1+cells were unaltered following chemotherapy. CD133+and Sca-1+cells exhibited increased stem cell-related gene expression, were enriched in G0/G1-early S phase and exhibited increased tumor initiating capacity, giving rise to heterogeneous tumors. Our findings suggest that residual TICs may contribute to recurrent disease.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2013.06.014